Paola Edith Padilla Noguera

Dr. Paola Edith Padilla Noguera

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of the International Association of Providers of AIDS Care (JIAPAC)
Verified
Journal Article
Open access
JNJuan Pablo Sánchez Navarro
Juan Pablo Sánchez Navarro
GAGustavo Barriga Angulo
Gustavo Barriga Angulo
JMJOSE Antonio MATA MARIN
JOSE Antonio MATA MARIN
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
PNPaola Edith Padilla Noguera
Paola Edith Padilla Noguera
JMJesús Enrique Gaytán Martínez
Jesús Enrique Gaytán Martínez
Background: The incidence of sexually transmitted infections (STIs) remains high among men who have sex with men (MSM) living with human immunodeficiency virus (HIV) (PWH). This study determined the prevalence of asymptomatic STIs in MSM PWH attending an HIV clinic in Mexico City. Methods: This cross-sectional study (May 2022-November 2023) included self-questionnaires on STI-related behaviors and symptoms, urethral samples for multiplex polymerase chain reaction (PCR), and serological tests for syphilis, HBV, and HCV. Results: Among 261 patients, 56.7% were receiving antiretroviral therapy, 41.8% had suppressed HIV-1 viral load, and 26.1% tested positive for at least one STI in urethral PCR. The most prevalent microorganisms were Ureaplasma urealyticum (14.9%), Mycoplasma hominis (6.9%), Mycoplasma genitalium (4.2%), and Chlamydia trachomatis (3.1%). Multiple infections were identified in 5.3% of cases. Seroprevalence rates for syphilis, HBV, and HCV were 17.6%, 6.5%, and 3.1%, respectively. Current smoking and insertive anal sex were the only statistically significant associated factors. Conclusions: This study underscores the high frequency of asymptomatic STIs and the importance of regular screening.

21 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
OLOmar Hernández López
Omar Hernández López
BGBrenda Clara González-Contreras
Brenda Clara González-Contreras
ADAna Luz Cano Díaz
Ana Luz Cano Díaz
JMJOSE Antonio MATA MARIN
JOSE Antonio MATA MARIN
Ericka Nelly Pompa-MeraEricka Nelly Pompa-Mera
Ericka Nelly Pompa-Mera
JGJesus Enrique Gaytan-Martínez
Jesus Enrique Gaytan-Martínez
Human papillomavirus (HPV) significantly contributes to anogenital cancers, with elevated risks among people living with HIV (PWH), particularly men who have sex with men (MSM). This study assessed anal HPV prevalence and associated risk factors in PWH in Mexico, focusing on the role of antiretroviral therapy (ART). Methods: A cross-sectional study at an HIV clinic in Mexico City (October 2023–December 2024) enrolled 214 MSM with HIV. The participants completed a validated risk factor questionnaire and provided anal samples for real-time PCR testing of 28 HPV genotypes. Logistic regression analyzed associations between HPV infection, ART regimens, and clinical/behavioral factors. Results: HPV prevalence was 89.3%, with HPV-16 (20.1%) being the most common high-risk genotype. Integrase inhibitor (INSTI) use was inversely associated with HPV-16 infection (OR: 0.42; 95% CI: 0.21–0.83; p = 0.011), while protease inhibitor use increased HPV-16 (OR: 2.16; 95% CI: 1.09–4.29; p = 0.025) and HPV-6 risks. Higher CD4+ counts (≥500 cells/mm3) and undetectable HIV viral load (<40 copies/mL) were protective against multiple HPV genotypes. Lower education and smoking increased HPV risk. Conclusions: This first Mexican study in the ART and HPV vaccination era highlights high anal HPV prevalence in PWH and suggests that INSTI-based regimens may reduce HPV-16 risk, informing ART selection for HPV prevention.

7 July 2026 in Cytopathology
Verified
Journal Article
Closed access
ADAna Luz Cano Díaz
Ana Luz Cano Díaz
OHOmar Hernández‐López
Omar Hernández‐López
JMJosé Antonio Mata‐Marín
José Antonio Mata‐Marín
JNJavier Vicente Noyola‐Gómez
Javier Vicente Noyola‐Gómez
SGSócrates Alberto García‐Gutiérrez
Sócrates Alberto García‐Gutiérrez
JGJesús Enrique Gaytan‐Martínez
Jesús Enrique Gaytan‐Martínez

18 November 2025 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
JMJosé Antonio Mata-Marín
José Antonio Mata-Marín
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
ADAna Luz Cano Díaz
Ana Luz Cano Díaz
MVMaría del Rosario Valenzuela-Salazar
María del Rosario Valenzuela-Salazar
ACAlberto Chaparro-Sánchez
Alberto Chaparro-Sánchez
JGJesús Enrique Gaytán-Martínez
Jesús Enrique Gaytán-Martínez
Background: Integrase strand transfer inhibitor (INSTI)-based regimens, such as dolutegravir/lamivudine/abacavir (DTG/3TC/ABC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), are recommended as first-line antiretroviral therapy (ART) for people living with HIV (PLH). This study compares their efficacy and safety in ART-naïve men living with HIV (MLH) in a real-world setting over 48 weeks. Methods: This open-label, randomized clinical trial (February 2021–October 2024) at Hospital de Infectología “La Raza” enrolled ART-naïve MLH with HIV-1 RNA ≥500 copies/mL and creatinine clearance >30 mL/min. Participants were randomized 1:1 to BIC/FTC/TAF or DTG/3TC/ABC. The primary endpoint was undetectable viral load (<50 copies/mL) at week 48, with safety assessed by adverse events (AEs) per DAIDS criteria. Results: Of 311 participants, 153 received BIC/FTC/TAF and 158 DTG/3TC/ABC. Virologic suppression was achieved in 90% of the BIC/FTC/TAF group and 86% of the DTG/3TCC/ABC group (p = 0.32). Median CD4+ counts were 649 cells/µL (BIC/FTC/TAF) and 723 cells/µL (DTG/3 TC/ABC) (p = 0.18). DTG/3TC/ABC had higher gastrointestinal AEs (21.5% vs 14.3%; p = 0.04) and grade 3 neuropsychiatric AEs. BIC/FTC/TAF showed higher insomnia rates. Abacavir-related hypersensitivity occurred in 0.6%. Conclusion: Both regimens showed high efficacy. BIC/FTC/TAF was more effective in patients with low baseline CD4 + counts, while DTG/3TC/ABC performed better with higher viral loads. DTG/3TC/ABC had more neuropsychiatric AEs and rare hypersensitivity reactions.